Onconetix, Inc. (ONCO) and Ocuvex Therapeutics, Inc. have entered into a definitive merger agreement under which Onconetix will acquire all issued and outstanding equity interests of Ocuvex.
Following the completion of the transaction, expected in the fourth quarter of this year, Onconetix’s board of directors will expand to seven members, with five appointed by Ocuvex and two by Onconetix.
Andrew J. Oakley, Chairman of the Board of Onconetix, expressed confidence that the merger, bringing a pipeline of commercial and late clinical stage ophthalmic assets, will deliver significant value to stockholders.
